

#### **INVESTOR RELEASE**

# VIVIMED ANNOUNCES ADDITIONAL INVESTMENT BY ORBIMED ASIA IN ITS OVERSEAS SUBSIDIARY VIVIMED LABS (MASCARENE) LTD

**Hyderabad**, India, January 1, 2018: Vivimed Labs Limited ("Vivimed" or the Company), a Pharmaceuticals and Specialty Chemicals Company, has signed definitive agreements and received funds to facilitate additional investment of USD 7.5mn (follow on of USD 42.5 mn invested in September 2017) by OrbiMed Asia into the Company's subsidiary, Vivimed Labs (Mascarene) Ltd, the holding entity of the Company's API business

# Commenting on the development, Mr. Santosh Varalwar, Managing Director said:

"Vivimed welcomes the additional follow on investment by OrbiMed Asia and this reiterates the confidence of the investor in the Vivimed Business model in the dynamic health care industry . The additional funds will fuel its growth opportunities overall.

Mr Saurabh Gurnurkar, Executive Director, Uquifa added, the proceeds of this additional investment will be utilised to drive business growth and, increase the Company's profitability by organic and inorganic Growth opportunities.

For further information on UQUIFA, visit www.uquifa.com

### **About Vivimed Labs:**

Vivimed is a Pharmaceuticals and Specialty Chemicals company headquartered in Hyderabad, India. It has manufacturing footprint across India, Europe and North America across its line of businesses and employs close to 2000 personnel across the world. Vivimed reported sales of about INR 15bn for the financial year ended March 31, 2017.

For further information on Vivimed, visit www.vivimedlabs.com

## About OrbiMed:

OrbiMed is a leading healthcare investment firm, with over \$14 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large MNCs, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Mumbai and Herzliya.

For VIVIMED LABS LTD.

Company Secretary



For further information please contact

**Company Contact:** 

Vivimed Labs Limited

CIN No: L02411KA1988PLC009465

Sunil Arab

Email: sunil.arab@vivimedlabs.com

B. Rajaprasad

Email: rajaprasad@vivimedlabs.com

**Investor Relations:** 

Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285

Rahul Agarwal

Email: rahul.agarwal@sgapl.net

Tel No: +91 79770 90416

Samantha Francis

Email: samantha.francis@sgapl.net

Tel No: +91 98330 06032

#### Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For VIVIMED LABS LTD.

Company Secretary